Q3 EPS Estimate for Viking Therapeutics Raised by Analyst

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Stock analysts at HC Wainwright raised their Q3 2026 earnings per share estimates for shares of Viking Therapeutics in a research note issued to investors on Thursday, July 30th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings of ($1.12) per share for the quarter, up from their prior forecast of ($1.15). The consensus estimate for Viking Therapeutics’ current full-year earnings is ($4.50) per share. HC Wainwright also issued estimates for Viking Therapeutics’ Q4 2026 earnings at ($1.14) EPS, FY2026 earnings at ($4.74) EPS and FY2027 earnings at ($6.04) EPS.

A number of other equities analysts also recently commented on the company. Zacks Research downgraded Viking Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, July 20th. Canaccord Genuity Group boosted their price objective on shares of Viking Therapeutics from $107.00 to $114.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Lake Street Capital initiated coverage on shares of Viking Therapeutics in a research report on Thursday, May 28th. They set a “buy” rating and a $89.00 price objective on the stock. Truist Financial started coverage on shares of Viking Therapeutics in a report on Wednesday, May 27th. They issued a “buy” rating and a $83.00 price objective for the company. Finally, Morgan Stanley set a $95.00 target price on shares of Viking Therapeutics in a research report on Thursday, April 30th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Viking Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $97.88.

Viking Therapeutics Stock Performance

Shares of VKTX stock opened at $32.94 on Monday. Viking Therapeutics has a fifty-two week low of $22.96 and a fifty-two week high of $43.15. The firm has a market cap of $3.84 billion, a P/E ratio of -7.07 and a beta of 0.69. The business’s 50 day moving average price is $34.24 and its 200-day moving average price is $32.98.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.10) EPS for the quarter, beating analysts’ consensus estimates of ($1.21) by $0.11. During the same period in the prior year, the business posted ($0.58) EPS. The business’s quarterly revenue was up .0% compared to the same quarter last year.

Hedge Funds Weigh In On Viking Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Concurrent Investment Advisors LLC increased its stake in shares of Viking Therapeutics by 1,624.0% in the 4th quarter. Concurrent Investment Advisors LLC now owns 281,052 shares of the biotechnology company’s stock worth $9,887,000 after acquiring an additional 264,750 shares in the last quarter. MH & Associates Securities Management Corp ADV bought a new stake in Viking Therapeutics during the fourth quarter worth about $1,535,000. Channel Wealth LLC bought a new stake in Viking Therapeutics during the fourth quarter worth about $2,655,000. Granahan Investment Management LLC grew its holdings in Viking Therapeutics by 41.0% in the first quarter. Granahan Investment Management LLC now owns 332,192 shares of the biotechnology company’s stock worth $10,810,000 after purchasing an additional 96,606 shares during the period. Finally, M&T Bank Corp grew its holdings in Viking Therapeutics by 605.1% in the fourth quarter. M&T Bank Corp now owns 69,914 shares of the biotechnology company’s stock worth $2,460,000 after purchasing an additional 59,998 shares during the period. Hedge funds and other institutional investors own 76.03% of the company’s stock.

Insider Transactions at Viking Therapeutics

In other news, CEO Brian Lian sold 148,517 shares of the stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $33.32, for a total value of $4,948,586.44. Following the completion of the transaction, the chief executive officer owned 2,572,441 shares of the company’s stock, valued at approximately $85,713,734.12. This represents a 5.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Marianna Mancini sold 18,217 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $33.47, for a total value of $609,722.99. Following the completion of the transaction, the chief operating officer owned 422,760 shares of the company’s stock, valued at approximately $14,149,777.20. The trade was a 4.13% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 187,951 shares of company stock valued at $6,268,442. Corporate insiders own 5.30% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.